Uksha Saini

Uksha Saini

Auto-generated profile, based on publicly available information

Uksha Saini

Center for Childhood Cancer Research, Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlexia K Martin
Alexia K Martin
JHJack Hedberg
Jack Hedberg
IAIlse Aguirre-Hernandez
Ilse Aguirre-Hernandez
USUksha Saini
Uksha Saini
DKDoyeon Kim
Doyeon Kim
KCKevin Cassady
Kevin Cassady
Background: Malignant gliomas (MG) are the most common primary brain malignancies and are considered universally fatal. Oncolytic HSVs (oHSV) are promising immunotherapeutics capable of selectively lysing cancer cells, eliciting anti-tumor immunity, and providing local delivery of immune-activating transgenes. IL-27 is a pleiotropic cytokine capable of enhancing tumor-reactive cytotoxic T cell (CTL) function while also possessing neuroprotective properties. We hypothesized that IL-27 expression by oHSV would enhance CTL function and improve anti-glioma therapeutic activity. Methods: We developed an oncolytic herpes simplex virus (oHSV) that expresses IL-27 (C027). The anti-glioma efficacy of C027 was tested in three syngeneic orthotopic glioma models derived from both chemical (CT-2A) and genetic (SB28, KR158) glioma lines. Spectral flow cytometry was used to assess immunophenotypic and functional changes in the tumor infiltrates and systemically. To further investigate the C027-related CTL activity, we employed in vivo cell specific depletion and IL-27 blockade alongside in vitro T cell stimulation assays. Local and systemic antitumor memory was evaluated by both orthotopic and flank tumor rechallenge of C027-treated long-term survivors. Results: C027 significantly prolonged survival in syngeneic orthotopic glioma models derived from both chemical (CT-2A) and genetic (KR158, SB28) glioma lines. In the CT-2A model, IL-27-expressing oHSV treatment was associated with increased intratumoral multifunctional effector cytotoxic T lymphocytes (CTL) and functional T cell populations systemically. Mechanistically, both CD8 T cells and IL-27 were required for the C027 survival benefit in vivo and IL-27 enhanced CTL function in vitro . C027-treated mice that survived their initial tumors had local and systemic anti-glioma memory rejecting tumors on rechallenge. Conclusions: Our findings demonstrate that IL-27 expression by oHSV significantly improves anti-glioma therapeutic efficacy, enhances CTL effector function, and induces durable immune memory. Thus, IL-27-oHSV may provide a promising therapeutic approach for malignant gliomas. What is already known on this topic – Malignant gliomas are highly aggressive tumors largely resistant to current immunotherapies. Oncolytic herpes simplex viruses (oHSV) are promising immunotherapy agents for malignant gliomas and provide a platform for immunomodulatory gene expression. What this study adds – In this study, we present a novel IL-27 expressing oHSV (C027) that improves survival in syngeneic glioma-bearing mice through a CD8 T cell and IL-27 dependent mechanism and induces durable immune memory. How this study might affect research, practice or policy – Our study demonstrates that IL-27-expression by oHSV enhances anti-tumor immunity and glioma efficacy suggesting its potential as a novel therapeutic.

17 March 2022 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
YCYaya Chu
Yaya Chu
MTMeijuan Tian
Meijuan Tian
KCKevin Cassady
Kevin Cassady
USUksha Saini
Uksha Saini
TCTimothy Cripe
Timothy Cripe
MCMitch S. Cairo
Mitch S. Cairo

7 November 2022 in Journal for ImmunoTherapy of Cancer
Verified
Conference Paper
Open access
PDF file
YCYaya Chu
Yaya Chu
MTMeijuan Tian
Meijuan Tian
USUksha Saini
Uksha Saini
DLDean Lee
Dean Lee
TCTimothy Cripe
Timothy Cripe
MCMitchell Cairo
Mitchell Cairo
Background Metastatic and relapsed/refractory neuroblastoma (NB) has very poor diagnosis.1 Novel therapies are desperately needed.2 ROR1 is overexpressed in a variety of human cancers including NB.3-5 Our group has successfully expanded peripheral blood NK cells (exPBNKs) and modified exPBNK cells to express chimeric antigen receptor (CAR).6. Oncolytic herpes simplex viruses (oHSVs) have been safely used in clinical trials for a wide range of cancers.7. IL-21 sustained the survival and increased the cytotoxicity of NK cells.8 We sought to determine the anti-tumor effect of anti-ROR1 CAR engineered exPBNK cells (CAR-exPBNKs) against ROR1+ NB and if the anti-tumor efficacy can be improved by oHSV engineered to express human IL21. Methods NK cells were expanded and electroporated with anti-ROR1-CAR mRNA. oHSV C134 was modified to express hIL-21 gene (C021). In-vitro cytotoxicity and cytokines levels of CAR-exPBNKs against NB cell lines were examined as we previously described (2). In-vivo hIL21 secretion and anti-tumor effect of CAR-exPBNKs with or without the C021 was examined utilizing human NB xenografted NSG mice. Results NK cells were significantly expanded by co-culture with irradiated K562-mbIL21 cells at 14 days (>2000 folds), and expanded NK cells were isolated with more than 95% purity. Anti-ROR1-CAR was expressed on >90% of exPBNK cells after CAR mRNA electroporation. CAR-exPBNK cells had significantly enhanced in-vitro cytotoxicity compared to Mock-exPBNK against ROR1+ SKNBE(2)N, CHLA-255, and SKNFI NB cells at different E:T ratios (p<0.001) regardless of MYCN amplification status. Expression of CD107a and IFN-g were significantly increased in CAR-exPBNK cells compared to Mock-exPBNK (p<0.05). CyTOF analysis showed that phosphorylation of STAT5 was enhanced in CAR-exPBNK when targeting NB as compared to exPBNK cells. In-vivo study showed that CAR-exPBNK significantly extended mice survival in human NB xenografted NSG mice (p<0.01) (figure 1). Furthermore, the combination of C021 and CAR-exPBNK significantly enhanced the killing of NB with significantly enhanced secretion of IFN-g, granzyme B and perforin and significantly enhanced expression of NK activating marker CD25 (all p<0.05) compared to controls. Our in-vivo animal study showed that NB infected with C021 secreted hIL21 and the combination of C021 and CAR-exPBNK cells reduced tumor burden in human NB xenografted NSG mice compared to the untreated group (p<0.05) and the CAR exPBNKs-treated group (P=0.056) (figure 2). Conclusions Our data demonstrate the significant anti-tumor efficacy of combining C021 with anti-ROR1 CAR-exPBNKs to therapeutically target NB in-vitro and in-vivo. (Funded by U54 CA232561). References Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) biology committee. Br J Cancer. 2009;100(9):1471–82. Epub 2009/04/30. doi: 6605014 [pii]. 10.1038/sj.bjc.6605014. PubMed PMID: 19401703; PubMed Central PMCID: PMC2694415. Chu Y, Nayyar G, Jiang S, Rosenblum JM, Soon-Shiong P, Safrit JT, et al. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice. J Immunother Cancer. 2021;9(7). Epub 2021/07/11. doi: 10.1136/jitc-2020-002267. PubMed PMID: 34244307; PubMed Central PMCID: PMCPMC8268924. Matsuda T, Nomi M, Ikeya M, Kani S, Oishi I, Terashima T, et al. Expression of the receptor tyrosine kinase genes, Ror1 and Ror2, during mouse development. Mech Dev. 2001;105(1-2):153–6. Epub 2001/06/29. doi: S0925477301003835 [pii]. PubMed PMID: 11429290. Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012;181(6):1903-10. PubMed PMID: 23041612. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013;19(12):3153–64. Epub 2013/04/27. doi: 1078-0432.CCR-13-0330 [pii]. 10.1158/1078-0432.CCR-13-0330. PubMed PMID: 23620405; PubMed Central PMCID: PMC3804130. Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, et al. Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice. Cancer Immunol Res. 2015;3(4):333–44. Epub 2014/12/11. doi: 10.1158/2326-6066.CIR-14-0114. PubMed PMID: 25492700. Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, et al. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. J Immunother Cancer. 2021;9(10). Epub 2021/10/03. doi: 10.1136/jitc-2021-002939. PubMed PMID: 34599026; PubMed Central PMCID: PMCPMC8488720. Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 2008;123(4):575–83. Epub 2007/11/17. doi: 10.1111/j.1365-2567.2007.02730.x. PubMed PMID: 18005035; PubMed Central PMCID: PMCPMC2433320. Ethics Approval NSG mice were bred, treated, and maintained in the animal facility of New York Medical College with NYMC International Animal Care and Use Committee approved protocols. The animal experiments were conducted in accordance with the recommendations of the Guide for Care and Use of Laboratory Animals. Anti-ROR-1 CAR NK significantly prolonged the survival of NSG mice xenografted with human NB cells C021+CAR-NK appeared to have a better anti-tumor effect than C134+CAR-NK in human NB xenografted NSG mice